Decision comes amid recommendation from agency’s Committee for Medicinal Products for Human Use.
Following the instructions of the European Commission (EC), Novartis has announced its removal of Adakveo (crizanlizumab) from the EU market. As a result of the agency’s Committee for Medicinal Products for Human Use (CHMP) recommending the action back in May, the EC has officially revoked conditional marketing authorization for the treatment. According to a company press release, the decision to rescind the conditional marketing authorization was based on a review of crizanlizumab under Article 20 of Regulation (EC) No 726/2004, initiated by the EC following the results of the phase III study, STAND (NCT03814746). The study reportedly did not emonstrate a statistically significant difference between crizanlizumab 5mg/kg or crizanlizumab 7.5mg/kg and placebo in annualized rates of vaso-occlusive crises leading to a healthcare visit over the first-year post randomization.
Currently, the medication remains in approval by the FDA for the reduction in frequency of vaso-occlusive crises in adults and pediatric patients aged 16 years or older with sickle cell disease.
Reference: European Commission (EC) adopts decision endorsing CHMP recommendation to revoke the conditional marketing authorization for Adakveo® (crizanlizumab). Novartis. August 4, 2023. Accessed August 7, 2023. https://www.novartis.com/news/european-commission-ec-adopts-decision-endorsing-chmp-recommendation-revoke-conditional-marketing-authorization-adakveo-crizanlizumab
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
2 Commerce Drive
Cranbury, NJ 08512